"The Open University was seeking a biosafety advisor for short to medium term support and our search led us to Bishop Simon. It was instantly apparent that they had the expertise to help us with the effective management of biological safety. Their first piece of work for us was an audit, making the process straightforward. The report was comprehensive, and we found the action plan clear and most useful in outlining our next improvement steps. We continue to be satisfied with their service, including genetic modification (GM) risk assessment reviews, GM committee advice and biosafety training and I’m happy recommend this company as a provider of interim biosafety support.” Jane Ball, CFIOSH, AIFireE  Head of Health and Safety at Open University

"I was seeking a biosafety practitioner with a proven track record. My company needed to work with one it could trust and who could move with speed to support us with our application to notify the HSE of our intention to carry out class 1 GM activity. Speed and certainty were crucial to take a product to market in as short a time as possible. Of the many personal and company profiles we came across, Bishop Simon stood out for all the right reasons, and showcased its ability to support biotech companies with GM safety matters. Within 1 month of working with the organisation, we attained our GM center number. We continue to work with Bishop Simon for support with future successful notifications, as well as other biosafety requirements.” Dr Aswin Doekhie  Co-Founder / Chief Technology Officer at EnsiliTech

“Bishop Simon supported Ascend GCTx in performing health and safety and biosafety audits, biological risk assessments, and HSE notification for use of HG2 agents for microbiological applications over the past year. Shurene, our lead consultant, was accommodating and timely, and ensured support throughout the work package lifecycle, providing expert insight on health, safety and biosafety requirements and best practice. I would recommend the consultancy to other bioscience organisations.” Abdullah Sufan  Downstream Processing Manager at Ascend Gene and Cell Therapy